Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Following these transactions, Leoni now holds 88,253 shares of the company. The sales were executed to cover taxes associated with the vesting of restricted stock units (RSUs) received in previous years. With the company’s next earnings report due on February 20, InvestingPro subscribers can access 10+ additional insights and detailed financial analysis to make informed investment decisions. With the company’s next earnings report due on February 20, InvestingPro subscribers can access 10+ additional insights and detailed financial analysis to make informed investment decisions.
Following these transactions, Leoni now holds 88,253 shares of the company. The sales were executed to cover taxes associated with the vesting of restricted stock units (RSUs) received in previous years.
In other recent news, Kura Oncology (NASDAQ:KURA), a pharmaceutical company specializing in cancer treatments, has secured a new headquarters in San Diego, California, according to a recent SEC filing. The company has also seen significant changes in its executive team with the departure of Stephen Dale, M.D., former Chief Medical (TASE:PMCN) Officer, and the appointment of Mollie Leoni, M.D. as the new Chief Medical Officer, and Francis Burrows, Ph.D. as the new Chief Scientific Officer.
In addition, Kura Oncology has expanded its stock option plan, reserving an additional 1.9 million shares, indicating an intent to attract top talent and expand its workforce. Lastly, the company has entered a strategic partnership with Kyowa Kirin, which includes a $330 million upfront payment and potential for up to $1.2 billion in total milestone payments, expected to fund and accelerate the development of ziftomenib, a promising treatment for acute myeloid leukemia (AML).
Analyst firms have also updated their outlook on Kura Oncology. Stifel reduced the price target to $11.00 from $18.00 while maintaining a Hold rating. Jefferies maintained a Buy rating but reduced the stock’s price target from $32.00 to $28.00. Meanwhile, H.C. Wainwright reaffirmed a Buy rating and raised the target price to $37.00. These updates followed the recent partnership and revised development trajectory for ziftomenib. These developments highlight Kura Oncology’s commitment to advancing its pipeline of oncology treatments and its strategic efforts to strengthen its position in the pharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.